Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death

Cancer Research

Volumn 61, Issue 1, 2001, Pages 138-144

  Wang, Y ^a   Liu, J ^a   Wu, Y ^a   Luo, W ^a   Lin, S H ^a   Lin, H ^a   Hawk, N ^a   Sun, T ^a   Guo, J Q ^a   Estrov, Z ^a   Talpaz, M ^a   Champlin, R ^a   Arlinghaus, R B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1NNEXIN; BCR ABL PROTEIN; BETA GALACTOSIDASE; PROTEIN TYROSINE KINASE; PYRANOSIDE; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL STRAIN COS1; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DELETION MUTANT; EXON; GENE EXPRESSION; HEMATOPOIETIC CELL; LEUKEMIA CELL; MOLECULAR CLONING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STAINING; STARVATION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL DIVISION; CELL SURVIVAL; COS CELLS; EXONS; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; ONCOGENE PROTEINS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCR; TRANSFECTION; TYROSINE;

EID: 0035138815     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. The involvement of Bcr in leukemias with the Philadelphia chromosome
2. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
3. Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
4. Inhibition of Bcr serine kinase by tyrosine phosphorylation
5. Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase
6. Sequences within the first exon of BCR inhibit the activated tyrosine kinase of c-Abl and the Bcr-Abl oncoprotein
7. Bcr: A negative regulator of the Bcr-Abl oncoprotein
8. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner
9. Human chronic myelogenous leukemia cell lines with positive Philadelphia chromosome
10. 1-positive human cell line (BV173)
11. Characterization of a novel human pre-B leukemia cell line
12. Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis
13. Tumor-suppressive activity of CD66a in prostate cancer
14. The cytoplasmic domain of C-CAM1 cell adhesion molecule is necessary and sufficient to suppress the tumorigenicity of prostate cancer cells
15. Manipulation of adenovirus vectors
16. BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy
17. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation
18. Gene transfer into human bone marrow hematopoietic cells mediated by adenovirus vectors
19. Adenoviral vectors and hematopoietic cells
20. Characterization of a monoclonal antibody revealed a novel binding epitope
21. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia
22. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia
23. Bcr and Bcr/Abl interaction: Cis and trans modes of tyrosine kinase inhibition
24. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage